Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells

BACKGROUND: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been used as first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, during treatment, cancer cells often develop resistance to gefitinib, the mechanisms of which are not fully understood...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shaojia, Liu, Chao, Lei, Qing, Wu, Zhengwei, Miao, Xiangshuai, Zhu, Debing, Yang, Xu, Li, Na, Tang, Mingwei, Chen, Yan, Wang, Weiwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114512/
https://www.ncbi.nlm.nih.gov/pubmed/33980216
http://dx.doi.org/10.1186/s12931-021-01719-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114512/
https://www.ncbi.nlm.nih.gov/pubmed/33980216
http://dx.doi.org/10.1186/s12931-021-01719-7

Ejemplares similares